10:17 AM
 | 
Aug 18, 2017
 |  BioCentury  |  Finance

Ante Antengene

Why Qiming invested in Chinese in-licensing play Antengene

With a track record of bringing drugs to market in China, the founder of Chinese in-licensing play Antengene Corp. convinced Qiming Venture Partners to lead its $21 million series A round.

Antengene closed the round on Aug. 16. TF Capital, HG Capital and Tigermed Investment, the venture arm of Chinese CRO Hangzhou Tigermed Consulting Co. Ltd. (SZSE:300347), also participated.

Antengene is Qiming’s third in-licensing play looking to target diseases prevalent in Asia. The others are Canbridge Life Sciences Ltd. and...

Read the full 397 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >